002932 Wuhan Easy Diagnosis Biomedicine
- 18.99
- -0.14-0.73%
Wuhan Easy Diagnosis Biomedicine News
Matilda Biotech (002932.SZ) 2023 equity distribution: 1.20 yuan for every 10 shares
According to Zhitong Finance App News, Matilda Biotech (002932.SZ) announced that the company's 2023 profit distribution plan is to distribute RMB 1.20 in cash (tax included) to all shareholders for every 10 shares based on the current total share capital. The share registration date for this equity distribution is: May 27, 2024, and the exclusion date is May 28, 2024.
Mingde Biotech (002932.SZ): 2.14% of shares have been repurchased cumulatively
Gelonghui, May 20, 丨 Matilda Biotech (002932.SZ) announced that up to May 20, 2024, the company had repurchased 4,966,031 shares of the company through a dedicated securities account, accounting for 2.14% of the company's total share capital; the highest transaction price for repurchased shares was 20.98 yuan/share, the minimum transaction price was 19.30 yuan/share, and the total transaction amount was RMB 100,042,919.81 (excluding transaction taxes and fees).
Mingde Biotech (002932.SZ): 1.60% of shares have been repurchased cumulatively
Gelonghui, May 6, 丨 Matilda Biotech (002932.SZ) announced that as of April 30, 2024, the company had repurchased 3,729,593 shares of the company's shares through a dedicated securities account, accounting for 1.60% of the company's total share capital; the highest transaction price of the repurchased shares was 20.98 yuan/share, the minimum transaction price was 19.3 yuan/share, and the total transaction amount was RMB 75,167,465.22 (excluding transaction tax).
Matilda Biotech (002932.SZ): Net profit of 32.0521 million yuan in the first quarter decreased by 57.52% year-on-year
On April 29, Ge Longhui (002932.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 609.634 million yuan, down 83.63% year on year; net profit attributable to shareholders of listed companies was 32.5521 million yuan, down 57.52% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 15.9706 million yuan; basic earnings per share of 0.14 yuan.
Mingde Biotech (002932.SZ): 1.32% of shares have been repurchased cumulatively
Gelonghui, April 16, 丨 Matilda Biotech (002932.SZ) announced that up to April 16, 2024, the company had repurchased 3,069,596 shares of the company through a dedicated securities account, accounting for 1.32% of the company's total share capital; the highest transaction price for repurchased shares was 20.98 yuan/share, the minimum transaction price was 19.41 yuan/share, and the total transaction amount was RMB 62,016,952.69 (excluding transaction taxes and fees).
Matilda Biology (002932.SZ): Dengue fever testing products already used in public health
Gelonghui, April 12 | Mingde Biotech (002932.SZ) said on the investor interactive platform that the company already has dengue fever testing products used in public health.
Mingde Biotech (002932.SZ): No products related to quantum dot liquid biochips
Gelonghui, March 29丨Mingde Biotech (002932.SZ) said on the investor interactive platform that the company has no products related to quantum dot liquid biochips, and that the company already has related products and layouts in electrochemical chips, multi-protein chips, etc.
Mingde Biotech (002932.SZ): Initial repurchase of 500,000 shares involving 9.944 million yuan
On March 27, Ge Longhui (002932.SZ) announced that on March 27, 2024, the company repurchased 500,000 shares of the company's shares through a dedicated securities account through centralized bidding, accounting for 0.215% of the company's total share capital; the highest transaction price of the repurchased shares was 20 yuan/share, the minimum transaction price was 19.69 yuan/share, and the total transaction amount was RMB 9.944 million (excluding transaction tax).
Matilda Biotech (002932.SZ): Actively laying out the application of AI in the field of CDSS
Gelonghui, March 26 | Mingde Biotech (002932.SZ) said on the investor interactive platform that the company is building a comprehensive solution for smart hospital testing, including molecular, blood gas, immunity, blood coagulation and other instruments and an information-based testing system for critical illness, as well as the development and production of wearable devices for patients. At the same time, the company is actively deploying AI in the field of CDSS (Clinical Decision Support System), mainly focusing on patient management, risk prediction, diagnosis and treatment assistance, treatment suggestions, case management, etc., to provide patients with more accurate and personalized decision support and improve the quality and efficiency of medical services.
Mingde Biotech (002932.SZ): As of March 20, 2024, the total number of shareholders of the company was 36513
Gelonghui March 21丨Mingde Biotech (002932.SZ) said on the investor interactive platform that as of March 20, 2024, the total number of shareholders of the company was 36,513.
Matilda Biotech (002932.SZ): There is currently no robotics business
Gelonghui, March 18 | Mingde Biotech (002932.SZ) said on the investor interactive platform that the company currently has no robotics business; the company's strategy of using cash on hand to seek mergers and acquisitions with high-quality companies in the same industry has not changed, and there is no intention to target the acquisition. If the acquisition progresses, the company will promptly fulfill its information disclosure obligations.
Matilda Biotech (002932.SZ): Plans to spend 175 million yuan to 350 million yuan to buy back the company's shares
Gelonghui March 1 | Mingde Biotech (002932.SZ) announced that the company plans to buy back the company's shares through centralized bidding transactions, which are intended to be used for employee stock ownership plans or equity incentives, and to protect the company's value and shareholders' rights. The total repurchase capital shall not be less than RMB 17,500.00 (inclusive), and not more than RMB 350,000 (inclusive). Among them, the total amount of repurchase capital used for employee stock ownership plans or equity incentives is not less than RMB 7,500.00 (inclusive) and not more than RMB 15,000.00 (inclusive) 10,000 yuan (inclusive) for shares used to protect the company's value and shareholders' rights
Mingde Biotech (002932.SZ): Head of finance changed to Wang Rui
Gelonghui, Feb. 6: Mingde Biotech (002932.SZ) announced that the company's board of directors recently received a written resignation report from Mr. Zhou Guohui, the company's financial director. Mr. Zhou Guohui applied to resign as head of company finance due to personal reasons. Nominated by the chairman, the board of directors of the company agreed to appoint Mr. Wang Rui as the financial director of the company. His term of office begins on the date of review and approval by the board of directors and ends on the date of expiration of the fourth board of directors.
Matilda Biology (002932.SZ): It already has testing products for cholera, dengue fever, measles, etc. used in public health
Gelonghui, Feb. 5 | Mingde Biotech (002932.SZ) said on the investor interactive platform that the company already has testing products for cholera, dengue fever, measles, etc. used in public health.
Mingde Biotech (002932.SZ): The Science and Technology Industrial Park is still under construction and is expected to be completed in batches in December 2024 and December 2025
Gelonghui January 31 丨 An investor asked Mingde Biotech (002932.SZ) on the investor interactive platform, “Have the R&D center and science park been put into use? What positive impact will it have on the future?” The company replied that the company's science and technology industrial park is still under construction and is expected to be completed in batches in December 2024 and December 2025. After the completion of the company's science and technology industrial park, it will expand the company's production scale, optimize the product structure, improve the process level, and comprehensively enhance the company's overall competitive strength and brand influence.
Mingde Biotech (002932.SZ) issued a pre-cut, and the net profit is expected to drop sharply from 55 million yuan to 75 million yuan by 98.22% to 98.69%
Matilda Biotech (002932.SZ) announced its 2023 annual results forecast. It is expected to be a listed company stock for the whole year...
Mingde Biotech (002932.SZ): As of January 19, 2024, the company had 36,397 common shareholders
Gelonghui, January 22丨Mingde Biotech (002932.SZ) said on the investor interactive platform that as of January 19, 2024, the company had 36,397 common shareholders.
Mingde Biotech (002932.SZ): As of January 10, 2024, the company had 36,699 common shareholders
Gelonghui, January 18 | Mingde Biotech (002932.SZ) said on the investor interactive platform that as of January 10, 2024, the company had 36,699 common shareholders.
Mingde Biology (002932.SZ): The company's in vitro diagnostic reagents are mainly used in laboratory departments and clinical departments of medical institutions
On January 16, Ge Longhui Biotech (002932.SZ) said on the investor interactive platform that the company's in vitro diagnostic reagents are mainly used in laboratory departments and clinical departments of medical institutions, and are suitable for patients of all ages.
Mingde Biotech (002932.SZ): Companies that have no plans to go public in the company's investment projects
Gelonghui, January 16 | Mingde Biotech (002932.SZ) said on the investor interactive platform that up to now, there are no plans to go public among the projects invested by the company.
Analysis
Price Target
No Data
